CL2020001075A1 - Amidas de imidazopiridina sustituidas y su uso - Google Patents

Amidas de imidazopiridina sustituidas y su uso

Info

Publication number
CL2020001075A1
CL2020001075A1 CL2020001075A CL2020001075A CL2020001075A1 CL 2020001075 A1 CL2020001075 A1 CL 2020001075A1 CL 2020001075 A CL2020001075 A CL 2020001075A CL 2020001075 A CL2020001075 A CL 2020001075A CL 2020001075 A1 CL2020001075 A1 CL 2020001075A1
Authority
CL
Chile
Prior art keywords
diseases
prophylaxis
treatment
substituted imidazopyridine
amides
Prior art date
Application number
CL2020001075A
Other languages
English (en)
Inventor
Kersten Matthias Gericke
Frank Wunder
Kirsten Leineweber
Daniel Meibom
Thomas Mondritzki
Alexander Straub
Klaus Münter
Jan Stampfuss
Karl Collins
Jutta Meyer
Hernandez Nuria Ortega
Till Freudenberger
Nina Alexandra Scheerer
Jens Schamberger
Walter Kroh
Mario Lobell
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020001075(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of CL2020001075A1 publication Critical patent/CL2020001075A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente solicitud se refiere a nuevas amidas de imidazopiridinas sustituidas de la fórmula (I), a procedimientos para su preparación, al uso de los mismos por sí solos o en combinación para el tratamiento y / o la profilaxis de enfermedades y al uso para la preparación de medicamentos para el tratamiento y / o la profilaxis de enfermedades, en particular para el tratamiento y / o la profilaxis de enfermedades cardiovasculares, neurológicas y del sistema nervioso central, así como enfermedades metabólicas.
CL2020001075A 2017-10-24 2020-04-22 Amidas de imidazopiridina sustituidas y su uso CL2020001075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24

Publications (1)

Publication Number Publication Date
CL2020001075A1 true CL2020001075A1 (es) 2021-01-22

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001075A CL2020001075A1 (es) 2017-10-24 2020-04-22 Amidas de imidazopiridina sustituidas y su uso

Country Status (27)

Country Link
US (1) US20200339567A1 (es)
EP (1) EP3700903A1 (es)
JP (1) JP2021500366A (es)
KR (1) KR20200076686A (es)
CN (1) CN111225917A (es)
AR (1) AR113790A1 (es)
AU (1) AU2018354785A1 (es)
BR (1) BR112020007967A2 (es)
CA (1) CA3084422A1 (es)
CL (1) CL2020001075A1 (es)
CO (1) CO2020004968A2 (es)
CR (1) CR20200173A (es)
CU (1) CU20200041A7 (es)
DO (1) DOP2020000072A (es)
EA (1) EA202091020A1 (es)
EC (1) ECSP20023043A (es)
IL (1) IL273954A (es)
JO (1) JOP20200073A1 (es)
MA (1) MA50440A (es)
MX (1) MX2020004190A (es)
NI (1) NI202000029A (es)
PE (1) PE20201280A1 (es)
PH (1) PH12020550472A1 (es)
SG (1) SG11202003641RA (es)
TW (1) TW201932462A (es)
UY (1) UY37947A (es)
WO (1) WO2019081353A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
AU2019401649B2 (en) 2018-12-20 2025-08-28 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (de) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
BR112023001952A2 (pt) 2020-08-05 2023-02-28 Massachusetts Gen Hospital Inibidores de quinase induzíveis por sal
US20240424053A1 (en) * 2021-11-09 2024-12-26 Tufts Medical Center, Inc. Methods and compositions for providing myocardial protection and treating myocardial stress and fibrosis
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
RU2004105035A (ru) 2001-07-20 2005-06-27 Ой Ювантиа Фарма Лтд (Fi) Соединения, полезные для лечения или профилактики заболевания, опосредованного альфа-2b-адреноцептором
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US7563797B2 (en) 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
EP2334676B1 (en) 2008-09-17 2016-07-06 Allergan, Inc. Substituted 3-amino-1-oxo or thioxo-1,2,5,6,7,8-hexahydro-2,7-naphthyridine-4-carbonitriles as selective alpha 2b antagonists
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
PL2539326T3 (pl) 2010-02-27 2017-10-31 Bayer Ip Gmbh Połączone bis-arylem arylotriazolony i ich zastosowanie
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2012105594A1 (ja) * 2011-02-01 2012-08-09 協和発酵キリン株式会社 縮環複素環誘導体
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US9309243B2 (en) 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
DK2875003T3 (en) 2012-07-20 2017-02-20 Bayer Pharma AG NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THE USE OF IT
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
BR112015020298A2 (pt) 2013-03-01 2017-07-18 Bayer Pharma AG pirimidinas de anel fundido substituídas com trifluormetil e uso das mesmas
KR20170081178A (ko) 2014-11-03 2017-07-11 바이엘 파마 악티엔게젤샤프트 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도

Also Published As

Publication number Publication date
KR20200076686A (ko) 2020-06-29
JOP20200073A1 (ar) 2020-04-29
IL273954A (en) 2020-05-31
CN111225917A (zh) 2020-06-02
MX2020004190A (es) 2020-08-03
AR113790A1 (es) 2020-06-10
AU2018354785A1 (en) 2020-04-23
WO2019081353A1 (de) 2019-05-02
CU20200041A7 (es) 2021-03-11
JP2021500366A (ja) 2021-01-07
DOP2020000072A (es) 2020-08-31
ECSP20023043A (es) 2020-06-30
SG11202003641RA (en) 2020-05-28
BR112020007967A2 (pt) 2020-10-20
UY37947A (es) 2019-05-31
CR20200173A (es) 2020-06-26
CO2020004968A2 (es) 2020-05-05
CA3084422A1 (en) 2019-05-02
EP3700903A1 (de) 2020-09-02
US20200339567A1 (en) 2020-10-29
TW201932462A (zh) 2019-08-16
PH12020550472A1 (en) 2021-03-15
NI202000029A (es) 2020-10-09
PE20201280A1 (es) 2020-11-24
MA50440A (fr) 2020-09-02
EA202091020A1 (ru) 2020-07-24

Similar Documents

Publication Publication Date Title
NI202000029A (es) Amidas de imidazopiridina sustituidas y su uso
UY37124A (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CO2017011851A2 (es) Compuestos novedosos
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
MX382331B (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer.
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
ECSP19044159A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CR20160558A (es) Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX370900B (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2020001506A2 (es) Nuevos compuestos
MX2017009608A (es) Compuestos anticancerigenos.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.